



# Correction: Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma

Luxin Yang · Yamin Tan · Jimin Shi · Yanmin Zhao · Yuanyuan Zhu · Yongxian Hu · Wenjue Pan · Yishan Ye · Jingsong He · Weiyan Zheng · Jie Sun · Zhen Cai · He Huang · Yi Luo

Published online: 15 June 2020

© The Author(s) 2020. This article is published with open access

Correction to: *Bone Marrow Transplantation*  
<https://doi.org/10.1038/s41409-018-0184-7>

The original version of this Article contained a mistake in Fig. 1 of non-relapse mortality (d). The solid line should represent the Allo-HSCT group and the dotted line should represent the Chemotherapy group. The description of the NRM of both groups in the figure's legend is correct. Below is the updated figure.

This has also been corrected in both the PDF and HTML versions of the Article.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.




Fig. 1